Literature DB >> 8153308

Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation.

R L Wahl1, L E Quint, R L Greenough, C R Meyer, R I White, M B Orringer.   

Abstract

PURPOSE: To evaluate use of positron emission tomography (PET) with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG) in detection of mediastinal lymph node metastases from non-small cell lung cancer.
MATERIALS AND METHODS: A prospective trial to compare FDG PET and computed tomography (CT) of the thorax was performed in 23 patients with newly diagnosed or suspected non-small cell lung cancer. Blinded interpretations of CT alone, PET alone, CT and PET together, and fusion images were performed, and the results were compared with pathologic results.
RESULTS: Nineteen of 23 patients had non-small cell lung cancer. Prevalence of mediastinal involvement was 41%. In staging disease in the mediastinum, CT alone was 64% sensitive, 44% specific, and 52% accurate, whereas PET alone and fusion images were 82% sensitive, 81% specific, and 81% accurate (P < .05).
CONCLUSIONS: FDG PET was more accurate than CT in staging disease in the mediastinum in patients with lung cancer and appears to be the preferred imaging method in this clinical setting.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8153308     DOI: 10.1148/radiology.191.2.8153308

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  54 in total

1.  Bone marrow involvement in breast cancer detected by positron emission tomography.

Authors:  C R Lewanski; G R Kaplan; J Potter; P Richman; R F Ashford; W L Wong
Journal:  J R Soc Med       Date:  1999-04       Impact factor: 5.344

2.  A versatile functional-anatomic image fusion method for volume data sets.

Authors:  M E Noz; G Q Maguire; M P Zeleznik; E L Kramer; F Mahmoud; J Crafoord
Journal:  J Med Syst       Date:  2001-10       Impact factor: 4.460

Review 3.  18-Fluorodeoxyglucose positron emission tomography (FDG-PET) and the staging of early lung cancer.

Authors:  G Laking; P Price
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

Review 4.  Positron emission tomography (PET) in the evaluation of patients with cancer.

Authors:  H A Godwin; J H Zuger
Journal:  Trans Am Clin Climatol Assoc       Date:  1999

5.  The impact of image fusion in resolving discrepant findings between FDG-PET and MRI/CT in patients with gynaecological cancers.

Authors:  Cheng-Chien Tsai; Chien-Sheng Tsai; Koon-Kwan Ng; Chyong-Huey Lai; Swei Hsueh; Pan-Fu Kao; Ting-Chang Chang; Ji-Hong Hong; Tzu-Chen Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-08-21       Impact factor: 9.236

6.  Requirements for clinical PET: comparisons within Europe.

Authors:  Michael Bedford; Michael N Maisey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

7.  MR/CT image fusion of the spine after spondylodesis: a feasibility study.

Authors:  C A Karlo; I Steurer-Dober; M Leonardi; C W A Pfirrmann; M Zanetti; J Hodler
Journal:  Eur Spine J       Date:  2010-05-15       Impact factor: 3.134

8.  Regional 2-[18F]fluoro-2-deoxy-D-glucose uptake varies in normal lung.

Authors:  T Miyauchi; R L Wahl
Journal:  Eur J Nucl Med       Date:  1996-05

9.  Oncologic positron emission tomography: a surgical perspective.

Authors:  Todd O Moore; Landis K Griffeth
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-01

Review 10.  Current role of positron emission tomography in thoracic oncology.

Authors:  V J Lowe; K S Naunheim
Journal:  Thorax       Date:  1998-08       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.